MedTrace Logo

A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm

NCT01905228 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2020-12-10

No results posted yet for this study

Summary

This is an open-label, multi-center, sequential groups, dose-escalation study of CBL0137 administered intravenously in participants with metastatic or unresectable advanced solid malignancies.

Conditions

Interventions

DRUG

CBL0137

All doses are administered intravenously on Days 1, 8 and 15 of every 28 day cycle. Number of Cycles: 2 or until progression or unacceptable toxicity develops

Sponsors & Collaborators

  • Incuron

    lead INDUSTRY

Principal Investigators

  • John Sarantopoulos, MD · The University of Texas Health Science Center at San Antonio

  • Renuka Iyer, MD · Roswell Park Cancer Institue

  • Afshin Dowlati, MD · University Hospital of Cleveland

  • Manmeet Ahluwalia, MD · The Cleveland Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2019-05-31
Completion
2019-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01905228 on ClinicalTrials.gov